We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 903.48 | 889.71 | 950.00 | 0 | 10:08:57 |
From May 2019 to May 2024
By Stephen Nakrosis
Regeneron Pharmaceuticals Inc. and Sanofi said Thursday a U.S. Phase 3 trial of Kevzara in Covid-19 patients didn't meet primary or key secondary endpoints.
The companies said the trial studied Kevzara, or sarilumab, in Covid-19 patients requiring mechanical ventilation. Results showed the trial "did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone."
The companies also said the "primary analysis group included 194 patients who were critically ill with Covid-19 and were receiving mechanical ventilation at the time of enrollment."
Based on the results, the companies said, the trial has been stopped. Results will be submitted to a peer-reviewed publication later this year, they added.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 02, 2020 17:07 ET (21:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
